Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

NEW YORK, Dec 10 (Reuters) - Online telehealth company Hims and Hers Health is launching its weight-loss membership and ...

Novo, however, vastly underestimated the appetite for its new weight-loss jab. Mr Doustdar says it planned for demand to be three times that of Saxenda, an older and less-effective weight-loss drug.

The move into the UK weight-loss category has been facilitated by the acquisition earlier this year of Zava, a London-based ...

The obesity drug producer has taken some hits throughout the past year, but it is beginning to punch back.

Novo Nordisk enters the final stretch of 2025 looking almost unrecognizable from the market darling it was just months ago.

Online telehealth company Hims and Hers Health HIMS.N is launching its weight-loss membership and treatment plans in the UK ...

One of largest U.S. telehealth providers expects to ride wave of exploding demand for weight-loss drug semaglutide when it ...

Hims and Hers first announced its expansion into Canada in early July, taking the opportunity as Danish pharmaceutical giant ...

Hims & Hers Health stock has seen its fair value estimate trimmed from about $46.00 to roughly $44.36 per share, even as analysts grow more optimistic about its long term revenue trajectory. Stronger ...

Hims Hers Health Inc (NYSE:HIMS) stock fell 4.4% Wednesday after U.S. lawmakers introduced legislation that could ...